The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma …
G Hapgood, J Butler, E Malan… - Thrombosis and …, 2013 - thieme-connect.com
Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
[引用][C] The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient …
G HAPGOOD, J BUTLER, E MALAN… - Thrombosis and …, 2013 - pascal-francis.inist.fr
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as
determined by the Hemoclot thrombin inhibitor assay in patient plasma samples CNRS Inist …
determined by the Hemoclot thrombin inhibitor assay in patient plasma samples CNRS Inist …
[PDF][PDF] The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient …
G Hapgood, J Butler, E Malan, S Chunilal… - Thrombosis and …, 2013 - academia.edu
Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma …
G Hapgood, J Butler, E Malan… - Thrombosis and …, 2013 - thieme-connect.com
Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
[PDF][PDF] The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient …
G Hapgood, J Butler, E Malan… - Thrombosis and …, 2013 - researchgate.net
Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma …
G Hapgood, J Butler, E Malan… - Thrombosis and …, 2013 - research.monash.edu
Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma …
J Butler, E Malan, S Chunilal, H Tran… - Thrombosis and …, 2013 - cir.nii.ac.jp
抄録< jats: title> Summary</jats: title>< jats: p> Dabigatran is an oral direct thrombin inhibitor
that does not require routine laboratory monitoring. However, an assessment of its …
that does not require routine laboratory monitoring. However, an assessment of its …
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma …
G Hapgood, J Butler, E Malan… - Thrombosis and …, 2013 - pubmed.ncbi.nlm.nih.gov
Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …
monitoring. However, an assessment of its anticoagulant effect in certain clinical settings is …